Abstract 1238P
Background
Identifying driver genes is crucial to make clinical decision for patients with non-small cell lung cancer (NSCLC). Except short turnaround time, higher success rate, it is still debating that PCR may cause false negative result due to its limited coverage. This study directly compared the performance of AmoyDx 11-gene PCR and NGS in the detection of known driver gene mutations in Chinese NSCLC patients.
Methods
FFPE samples from a total of 765 Chinese NSCLC patients were collected. The test performance of AmoyDx 11-gene PCR (EGFR, KRAS, ALK, HER2, ROS1, MET, BRAF, NTRK1/ 2/3, and RET) and NGS were compared.
Results
The overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) between AmoyDx 11-gene PCR and NGS were 98.8%, 99.3%, and 97.1%, respectively (Table). The PPA between the two assays were the same (100.0%) in common drivers (EGFR/KRAS/ALK) and rare drivers, the OPA and NPA were higher in rare drivers (99.5% vs. 99.9% and 98.8% vs. 99.8%) in AmoyDx 11-gene PCR. For rare drivers, concordance between PCR and NGS were shown in HER2 (OPA: 99.7%, PPA: 95.1% and NPA: 100.0%), ROS1 (OPA: 99.9%, PPA: 100.0% and NPA: 99.9%), MET (OPA:99.9%, PPA:96.4% and NPA:100.0%), BRAF and RET (OPA: 100.0%, PPA: 100.0% and NPA: 100.0%), respectively. Most of interestingly, for EGFR exon 20 insertion (EGFR ex20ins), a good concordance rate of 99.6% (PPA: 100.0% and NPA: 99.6%) was achieved. Table: 1238P
Comparison of AmoyDx 11-gene PCR and NGS for detecting known driver genes in NSCLC patients
NGS (mutant) | NGS (wild) | OPA | PPA | NPA | ||
Total drivers | PCR (mutant) | 591 | 5 | 98.8% | 99.3% | 97.1% |
PCR (wild) | 4 | 165 | ||||
Common drivers | PCR (mutant) | 425 | 4 | 99.5% | 100.0% | 98.8% |
PCR (wild) | 0 | 336 | ||||
Rare drivers | PCR (mutant) | 156 | 1 | 99.9% | 100.0% | 99.8% |
PCR (wild) | 0 | 608 | ||||
EGFR exon20ins | PCR (mutant) | 24 | 3 | 99.6% | 100.0% | 99.6% |
PCR (wild) | 0 | 738 | ||||
HER2 | PCR (mutant) | 39 | 0 | 99.7% | 95.1% | 100.0% |
PCR (wild) | 2 | 724 | ||||
ROS1 | PCR (mutant) | 19 | 1 | 99.9% | 100.0% | 99.9% |
PCR (wild) | 0 | 745 | ||||
BRAF | PCR (mutant) | 19 | 0 | 100.0% | 100.0% | 100.0% |
PCR (wild) | 0 | 746 | ||||
RET | PCR (mutant) | 25 | 0 | 100.0% | 100.0% | 100.0% |
PCR (wild) | 0 | 740 | ||||
MET | PCR (mutant) | 27 | 0 | 99.9% | 96.4% | 100.0% |
PCR (wild) | 1 | 737 |
Conclusions
AmoyDx 11-gene PCR displayed high concordance to NGS in detecting driver mutations of NSCLC, especially rare drivers (EGFR ex20ins), suggesting it is an excellent choice in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Li, F. Gai, C. Zhu: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1204TiP - Iadademstat in combination with paclitaxel in relapsed/refractory small cell lung carcinoma (SCLC) and extrapulmonary high grade neuroendocrine carcinoma (NEC)
Presenter: Neel Belani
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14